Efficacy  	Efficacy  	 NNP	O
and  	and  	 CC	O
safety  	safety  	 NN	O
evaluation  	evaluation  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
novel  	novel  	 NN	B-NP
botulinum  	botulinum  	 NN	I-NP
toxin  	toxin  	 NN	I-NP
topical  	topical  	 NN	I-NP
gel  	gel  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
moderate  	moderate  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
lateral  	lateral  	 JJ	B-NP
canthal  	canthal  	 JJ	I-NP
lines  	lines  	 NNS	I-NP
Botulinum  	Botulinum  	 JJ	I-NP
toxin  	toxin  	 NN	I-NP
type  	type  	 NN	I-NP
A  	A  	 DT	O
( 	( 	 -LRB-	O
BoNTA 	BoNTA 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
commonly  	commonly  	 RB	O
injected  	injected  	 VBN	O
to  	to  	 TO	O
treat  	treat  	 VB	O
facial  	facial  	 JJ	B-NP
wrinkles 	wrinkles 	 NN	I-NP
.  	.  	 .	O
Complications  	Complications  	 NNS	B-NP
include  	include  	 VBP	O
pain 	pain 	 NN	O
,  	,  	 ,	O
erythema 	erythema 	 NN	B-NP
,  	,  	 ,	O
bruising 	bruising 	 VBG	O
,  	,  	 ,	O
and  	and  	 CC	O
potential  	potential  	 JJ	B-NP
infection 	infection 	 NN	I-NP
.  	.  	 .	O
RT001  	RT001  	 NNP	B-NP
Botulinum  	Botulinum  	 NNP	I-NP
Toxin  	Toxin  	 NNP	I-NP
Type  	Type  	 NNP	I-NP
A  	A  	 NNP	O
Topical  	Topical  	 NNP	B-NP
Gel  	Gel  	 NNP	I-NP
( 	( 	 -LRB-	O
RT001 	RT001 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
under  	under  	 IN	O
development  	development  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
lateral  	lateral  	 JJ	B-NP
canthal  	canthal  	 JJ	I-NP
lines  	lines  	 NNS	I-NP
( 	( 	 -LRB-	O
LCLs 	LCLs 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
To  	To  	 TO	O
assess  	assess  	 VB	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
of  	of  	 IN	O
RT001  	RT001  	 CD	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
LCLs  	LCLs  	 JJ	O
using  	using  	 VBG	O
a  	a  	 DT	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
double-blind 	double-blind 	 NNP	B-NP
,  	,  	 ,	O
repeat-dose 	repeat-dose 	 NNP	B-NP
,  	,  	 ,	O
placebo-controlled  	placebo-controlled  	 JJ	O
study  	study  	 NN	O
design 	design 	 NN	O
.  	.  	 .	O
Healthy  	Healthy  	 JJ	B-NP
adult  	adult  	 NN	I-NP
subjects  	subjects  	 NNS	I-NP
were  	were  	 VBD	O
randomized  	randomized  	 VBN	O
to  	to  	 TO	O
receive  	receive  	 VB	O
RT001  	RT001  	 NNP	B-NP
( 	( 	 -LRB-	O
N=19 	N=19 	 NNP	O
)  	)  	 -RRB-	O
or  	or  	 CC	O
placebo  	placebo  	 NNS	O
( 	( 	 -LRB-	O
N=17 	N=17 	 NNP	O
)  	)  	 -RRB-	O
applied  	applied  	 VBD	O
to  	to  	 TO	O
their  	their  	 PRP$	O
lateral  	lateral  	 JJ	B-NP
canthal  	canthal  	 JJ	I-NP
areas  	areas  	 NNS	I-NP
( 	( 	 -LRB-	O
LCAs 	LCAs 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
To  	To  	 TO	O
evaluate  	evaluate  	 VB	O
safety  	safety  	 NN	O
of  	of  	 IN	O
repeat  	repeat  	 NN	B-NP
exposure 	exposure 	 NN	I-NP
,  	,  	 ,	O
treatment  	treatment  	 NN	O
was  	was  	 VBD	O
administered  	administered  	 VBN	O
at  	at  	 IN	O
baseline  	baseline  	 NN	B-NP
and  	and  	 CC	O
week  	week  	 NN	B-NP
4 	4 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
primary  	primary  	 JJ	B-NP
efficacy  	efficacy  	 JJ	I-NP
measure  	measure  	 NN	I-NP
was  	was  	 VBD	O
improvement  	improvement  	 NN	O
in  	in  	 IN	O
baseline  	baseline  	 JJ	B-NP
LCL  	LCL  	 NNP	I-NP
severity  	severity  	 NN	I-NP
using  	using  	 VBG	O
the  	the  	 DT	O
Investigator 	Investigator 	 NNP	B-NP
's  	's  	 POS	I-NP
Global  	Global  	 NNP	I-NP
Assessment  	Assessment  	 NNP	I-NP
of  	of  	 IN	I-NP
Lateral  	Lateral  	 NNP	I-NP
Canthal  	Canthal  	 NNP	I-NP
Line  	Line  	 NNP	I-NP
at  	at  	 IN	O
Rest  	Rest  	 NNP	O
( 	( 	 -LRB-	O
IGA-LCL 	IGA-LCL 	 NNP	B-NP
)  	)  	 -RRB-	O
Severity  	Severity  	 NNP	B-NP
Scale 	Scale 	 NNP	I-NP
.  	.  	 .	O
At  	At  	 IN	O
8  	8  	 CD	O
weeks 	weeks 	 NNS	O
,  	,  	 ,	O
19  	19  	 CD	O
( 	( 	 -LRB-	O
50 	50 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
LCAs  	LCAs  	 JJ	B-NP
treated  	treated  	 NN	I-NP
with  	with  	 IN	O
RT001  	RT001  	 NNP	B-NP
showed  	showed  	 VBD	O
a  	a  	 DT	O
2-point  	2-point  	 NNP	O
or  	or  	 CC	O
greater  	greater  	 JJR	O
improvement  	improvement  	 NN	O
in  	in  	 IN	O
baseline  	baseline  	 JJ	B-NP
IGA-LCL  	IGA-LCL  	 JJ	I-NP
severity 	severity 	 NN	I-NP
,  	,  	 ,	O
versus  	versus  	 CC	O
none  	none  	 NN	O
( 	( 	 -LRB-	O
0 	0 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
placebo-treated  	placebo-treated  	 JJ	O
subjects  	subjects  	 NNS	B-NP
( 	( 	 -LRB-	O
p  	p  	 FW	O
< 	< 	 SYM	O
.001 	.001 	 FW	O
) 	) 	 -RRB-	O
;  	;  	 :	O
36  	36  	 CD	O
( 	( 	 -LRB-	O
94.7 	94.7 	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
LCAs  	LCAs  	 JJ	B-NP
treated  	treated  	 NN	I-NP
with  	with  	 IN	O
RT001  	RT001  	 NNP	B-NP
showed  	showed  	 VBD	O
a  	a  	 DT	O
1-point  	1-point  	 NNP	O
or  	or  	 CC	O
more  	more  	 JJR	O
improvement  	improvement  	 NN	O
in  	in  	 IN	O
baseline  	baseline  	 JJ	B-NP
IGA-LCL  	IGA-LCL  	 JJ	I-NP
severity 	severity 	 NN	I-NP
,  	,  	 ,	O
versus  	versus  	 CC	O
five  	five  	 CD	O
( 	( 	 -LRB-	O
14.7 	14.7 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
placebo-treated  	placebo-treated  	 NNP	O
LCAs  	LCAs  	 NNP	B-NP
( 	( 	 -LRB-	O
p  	p  	 FW	O
< 	< 	 SYM	O
.001 	.001 	 FW	O
) 	) 	 -RRB-	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
no  	no  	 DT	O
treatment-related  	treatment-related  	 JJ	O
adverse  	adverse  	 JJ	O
events 	events 	 NNS	O
.  	.  	 .	O
RT001  	RT001  	 NNP	B-NP
was  	was  	 VBD	O
well  	well  	 RB	O
tolerated  	tolerated  	 JJ	O
and  	and  	 CC	O
demonstrated  	demonstrated  	 VBD	O
an  	an  	 DT	O
improvement  	improvement  	 NN	O
in  	in  	 IN	O
LCLs 	LCLs 	 JJ	O
.  	.  	 .	O
